Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi




http://scihub22266oqcxt.onion/
suck pdf from google scholar
32558435!ä!32558435
PDF vom PMID32558435 :   free

suck abstract from ncbi

pmid32558435
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond #MMPMID32558435
  • Bridgewood C; Damiani G; Sharif K; Watad A; Bragazzi NL; Quartuccio L; Savic S; McGonagle D
  • Isr Med Assoc J 2020[Jun]; 22 (6): 335-339 PMID32558435show ga
  • BACKGROUND: In the absence of definitive anti-viral therapy, there is considerable interest in mitigating against severe inflammatory reactions in coronavirus disease-2019 (COVID-19) pneumonia to improve survival. These reactions are sometimes termed cytokine storm. PDE4 inhibitors (PDE4i) have anti-inflammatory properties with approved indications in inflammatory skin and joint diseases as well as chronic obstructive pulmonary disease (COPD). Furthermore, multiple animal models demonstrate strong anti-inflammatory effects of PDE4i in respiratory models of viral and bacterial infection and also after chemically mediated lung injury. The rationale for PDE4i use in COVID-19 patients comes from the multimodal mechanism of action with cytokine, chemokine, and other key pathway inhibition all achieved with an excellent safety profile. We highlight how PDE4i could be an overlooked treatment from the rheumatologic and respiratory armamentarium, which has potential beneficial immune-modulation for treating severe COVID-19 pneumonia associated with cytokine storms. The proposed use of PDE4i is also supported by age-related immune changes in inflammation severity in PDE4i modifiable pathways in primate coronavirus disease. In conclusion, over-exuberant anti-viral immune responses in older patients with COVID-19 may pose a substantial risk to patient survival and mitigation against such hyper-inflammation with PDE4i, especially with anti-viral agents, is a strategy that need to be pursed, especially in older patients.
  • |*Disease Outbreaks[MESH]
  • |Adult[MESH]
  • |Age Factors[MESH]
  • |Aged[MESH]
  • |Animals[MESH]
  • |Anti-Inflammatory Agents/*administration & dosage[MESH]
  • |Betacoronavirus[MESH]
  • |COVID-19[MESH]
  • |Communicable Diseases, Emerging/*drug therapy/mortality[MESH]
  • |Coronavirus Infections/diagnosis/*drug therapy/*epidemiology[MESH]
  • |Female[MESH]
  • |Humans[MESH]
  • |Italy[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Pandemics[MESH]
  • |Phosphodiesterase 4 Inhibitors/*administration & dosage/pharmacology[MESH]
  • |Pneumonia, Viral/diagnosis/*drug therapy/*epidemiology[MESH]
  • |Prognosis[MESH]
  • |Risk Assessment[MESH]
  • |SARS-CoV-2[MESH]
  • |Survival Analysis[MESH]
  • |Treatment Outcome[MESH]
  • |United Kingdom[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    335 6.22 2020